Therapeutics News

Open-angle glaucoma patients who lowered their intraocular pressure with latanoprost demonstrated more visual field preservation than a placebo group, researchers reported in a study recently published in The Lancet.

The January 2015 print issue of Primary Care Optometry News tackles topics from myopia control to cyberliability to treating presbyopia with topical drops to inexpensive treatment options.

As part of Primary Care Optometry News’ 20th anniversary celebration, in each issue throughout 2015 we will profile a “Pioneer in Optometry” as chosen by the PCON Editorial Board.

In cases where patients have no insurance or have limited prescription coverage, a management plan can be challenging.

Patients in the U.S. with presbyopia are currently treated with spectacles, multifocal contact lenses or multifocal IOLs, with a number of other surgical treatments not yet approved. However, at least three companies are investigating noninvasive options for treating presbyopia with topical drops.

The treatment of inflammatory ocular disease is becoming more exciting.

The ocular nonsteroidal anti-inflammatory nepafenac aided the efficacy of prostaglandin analogs, according to a study recently published in the Journal of Glaucoma.

A study comparing four concentrations of latanoprostene bunod with latanoprost 0.005% showed that latanoprostene bunod 0.024% led to significantly greater reductions in diurnal IOP than latanoprost.

DENVER – Patients treated with lifitegrast showed improvement in symptoms but not signs of dry eye, according to a presenter here at the American Academy of Optometry meeting.

Researchers evaluated the results of 17 studies involving 807 patients and determined that latanoprost as monotherapy effectively reduced intraocular pressure in those with angle-closure glaucoma.